FINDINGS: Wednesday, August 12th

How Did You Learn of the Event?

The majority, 63%, said that they learned of it from 50 Hoops; 19% were guests, 16% learned of it from other and 2% learned of it from Linked-In.

Where Are You Now?

The majority, 84%, were at home; 12% were in an office, 2% were in a car and the same percentage, 2%, were with family and friends.
Have you ever...

**Attended a Prior 50 Hoops Event?**

- Yes 63%
- No 37%

The majority, 63%, had attended a prior 50 Hoops event and 37% had not.

**AACT I Scene**

**Level of Health if Had Lung Cancer**

(10=Excellent; 1=Poor)

- Level-10: 33%
- Level-1: 33%
- Level-8: 17%
- Level-5: 17%

There was a tie, 33% of the respondents said that their health was excellent and 33% said that their health was poor if they had lung cancer. It was a tie, again, with 17% who felt that their health was at level 8 and 17% who felt that their health was at level 5, if they had lung cancer.
The majority, 66%, had excellent health if they had Multiple Myeloma; there was a tie, 17% at level 6 and 17% were at level 2 if they had Multiple Myeloma.

The majority, 67%, had excellent health if they had prostate cancer; 33% had almost the same level, level 9, if they had prostate cancer.
The majority, 66%, had a level 10, (excellent) if they had COVID-19. Then 17% had a level 7, and 17% level 1.

AACT Scene II

The majority, 34%, would be extremely likely to join a clinical study on Multiple Myeloma; 13% were a less than extremely likely, level 8 and level 7, and level 1, who were not at all likely to consider joining a clinical study. Also 9% were at levels of 5 and 6 and even 3 in terms of considering a clinical study on Multiple Myeloma.
The majority, 31%, would be extremely likely to join a clinical study on prostate cancer. Then 15% of those who were at a level of 8 would consider joining a prostate cancer clinical Study; 10% were at level 1, would not at all consider it and 10% were at level 6 and level 7. Then 6% would be at levels 9, 4, 3, and 5.

The majority, 33%, were at level 8 in considering joining a clinical study on lung Cancer; 24% were at level 1%, would not at all consider joining a clinical study on lung cancer. There were 14% who were at the level 5, mid-point in considering joining a study on lung cancer; 9% were tied at levels 6 and 9; 5% were also tied at levels 7 and 4 in considering joining a clinical study on lung cancer.
The majority, 42%, were at level 10, would be extremely likely to join a clinical study on COVID-19; 13%, were at level 1, not at all likely to consider joining a clinical study on COVID-19. Then 10% were tied at level 5, the midpoint level, and at level 4%; 6% were at levels 7, 6, and 9; 3% were tied at levels 8 and 3.

AACTI/Scene III
Based upon the Panel presentations, which disease do you think your community would be most interested?

The majority of the community were most interested in the COVID-19 panel presentation.
Based upon the Clinical Study’s presentations, which disease do you think your community would be most interested?

The clinical study most of interest to the community was also COVID-19.

Of the diseases and clinical studies discussed today, how would you rate:

**Interest in Joining a Clinical Study in Multiple Myeloma (giving plasma)**

- May be interested
- Would not be interested
- Very interested

The majority, 61%, may be interested in joining a clinical study in Multiple Myeloma; 30% would not be interested and 9% would be interested.
The majority, 46%, may be interested in joining a clinical study in prostate cancer; 42% would not be interested and 12% would be interested.

The majority, 45%, may be interested in joining a clinical study in lung cancer; 43% would not be interested and 12% would be interested.
The majority, 55%, may be interested in joining a clinical study in Multiple Myeloma; 26% would not be interested and 19% would be interested.
The majority, 85% did have a church, club or network interested in hearing more about clinical Studies in African American communities and only 15% said no they did not.

On a scale of 1-10, would you be willing to:
The majority, 36%, said that they were at level 5, the midpoint, in participating in a clinical Study that used their insurance. The next largest group, 29%, would be extremely likely to participate; 14% were at both level 9 and level 7 in participating and 7% were at level 8.

On a scale of 1-10, would you be willing to:

<table>
<thead>
<tr>
<th>Level</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level-10</td>
<td>36%</td>
</tr>
<tr>
<td>Level-8</td>
<td>21%</td>
</tr>
<tr>
<td>Level-5</td>
<td>21%</td>
</tr>
<tr>
<td>Level-9</td>
<td>14%</td>
</tr>
<tr>
<td>Level-7</td>
<td>7%</td>
</tr>
</tbody>
</table>

The majority, 36%, would be extremely likely to participate in a clinical study for African Americans that helps discover a cure for a disease; 21% were tied at levels 8 and 5; 14% indicated that they were at level 9 in terms of likelihood of participating and 7% indicated that they were at level 7.
ACCTII Scene II

The majority, 29%, would be at level 9 in terms of the likelihood of giving blood or plasma as part of a clinical study to save their child, parent or community; 14% said that they would equally at levels 10, extremely likely, 8, 7, and 3.
The majority were tied with 19% at level 10, extremely likely, at level 5, the midpoint, and level 1, not at all likely to join a clinical trial with injection as part of the treatment; 15% were at level 3 in their likelihood of joining; 8% were at level 7 and 8% were at level 2; 4% were at levels 9, 8, and 4.
The majority, 36%, were at level 10, extremely likely, to join a trial where you take on or more pills as part of a cure or treatment; 16% were at level 8; 12% were at level 5, midpoint. There were 8% at levels 9, 6, 3, and 7. Only 4% were at level 1, not at all likely to join a trial where you take on or more pills as part of a cure or treatment.
The majority, 76%, were interested in receiving COVID-19 clinical studies vaccine results and 24% said that they would not be interested.

The majority, 29%, were at the level 9 of participating in a clinical trial that would be beneficial to them by improving treatment or discovering a cure; 14% were at levels of 10, 8, 7, 6, and 3.
The majority, 60%, rated McCaW as excellent; 36% found it very interesting; and 4% found that it kept their attention.

Be Willing to Participate in a Zoom Information Meeting About Clinical Trials?
100% said Yes.

Speaker Topics

The majority, 58%, said prostate cancer; 19% said Lung cancer; 15% said Multiple Myeloma and 8% said COVID-19.
Poll 4: CTA
Willing to get at least 4 other people to join the next McCaW?

There were 62% who said yes, they would contact 4 other people to join the next McCaW; 27% said that they would probably do; 11% said maybe.

Reach Participants

The majority, 86%, said that the best way to reach participants was email; 7% said either and 7% said cellphones.